BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16841083)

  • 21. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.
    Rudolph-Owen LA; Chan R; Muller WJ; Matrisian LM
    Cancer Res; 1998 Dec; 58(23):5500-6. PubMed ID: 9850086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types.
    Cadieux C; Kedinger V; Yao L; Vadnais C; Drossos M; Paquet M; Nepveu A
    Cancer Res; 2009 Sep; 69(18):7188-97. PubMed ID: 19738070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of mouse mammary tumour virus (MMTV)/neu transgenic mice to identify genes collaborating with the c-erbB-2 oncogene in mammary tumour development.
    Jolicoeur P; Bouchard L; Guimond A; Ste-Marie M; Hanna Z; Dievart A
    Biochem Soc Symp; 1998; 63():159-65. PubMed ID: 9513720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
    Vertuani S; Triulzi C; Roos AK; Charo J; Norell H; Lemonnier F; Pisa P; Seliger B; Kiessling R
    Cancer Immunol Immunother; 2009 May; 58(5):653-64. PubMed ID: 18820911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice.
    Ritland SR; Rowse GJ; Chang Y; Gendler SJ
    Cancer Res; 1997 Aug; 57(16):3520-5. PubMed ID: 9270023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
    Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
    Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity.
    Rickard S; Ono SJ
    Exp Mol Pathol; 2008 Dec; 85(3):147-54. PubMed ID: 18952077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
    Sas S; Chan T; Sami A; El-Gayed A; Xiang J
    Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype.
    Lu X; Kallinteris NL; Li J; Wu S; Li Y; Jiang Z; Hillman GG; Gulfo JV; Humphreys RE; Xu M
    Cancer Immunol Immunother; 2003 Oct; 52(10):592-8. PubMed ID: 12827305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
    Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W
    Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
    Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
    Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice.
    Takeuchi N; Hiraoka S; Zhou XY; Nagafuku M; Ono S; Tsujimura T; Nakazawa M; Yura Y; Hamaoka T; Fujiwara H
    Cancer Res; 2004 Oct; 64(20):7588-95. PubMed ID: 15492286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
    Zinser GM; Welsh J
    Carcinogenesis; 2004 Dec; 25(12):2361-72. PubMed ID: 15333467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
    Amici A; Smorlesi A; Noce G; Santoni G; Cappelletti P; Capparuccia L; Coppari R; Lucciarini R; Petrelli C; Provinciali M
    Gene Ther; 2000 Apr; 7(8):703-6. PubMed ID: 10800094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.
    Jacquemart IC; Springs AE; Chen WY
    Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
    Ursini-Siegel J; Rajput AB; Lu H; Sanguin-Gendreau V; Zuo D; Papavasiliou V; Lavoie C; Turpin J; Cianflone K; Huntsman DG; Muller WJ
    Mol Cell Biol; 2007 Sep; 27(18):6361-71. PubMed ID: 17636013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimetastatic activity of a preventive cancer vaccine.
    Nanni P; Nicoletti G; Palladini A; Croci S; Murgo A; Antognoli A; Landuzzi L; Fabbi M; Ferrini S; Musiani P; Iezzi M; De Giovanni C; Lollini PL
    Cancer Res; 2007 Nov; 67(22):11037-44. PubMed ID: 18006850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors.
    Chen Y; Hu D; Eling DJ; Robbins J; Kipps TJ
    Cancer Res; 1998 May; 58(9):1965-71. PubMed ID: 9581840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.
    Pulaski BA; Ostrand-Rosenberg S
    Cancer Res; 1998 Apr; 58(7):1486-93. PubMed ID: 9537252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.